Search Results

Gore’s Viabahn Fortegra Venous Stent Wins FDA Approval

January 6, 2026—Gore & Associates announced FDA approval of the Gore Viabahn Fortegra venous stent—previously known as the Gore Viafort vascular stent—for the treatment of deep venous disease in the inferior vena cava (IVC), iliac, and iliofemoral veins.

Pain and QoL Data Presented for Gore’s Viabahn Fortegra Venous Stent

April 22, 2026—Gore & Associates announced new 12-month findings from the global GORE VIABAHN FORTEGRA Venous Stent IVC trial, which evaluated treatment of patients with symptomatic deep venous iliocaval obstruction.

Gore Viafort Vascular Stent IVC Study Enrolls First US Patient

March 28, 2023—Gore & Associates announced that the first patient in the United States has been enrolled in the pivotal Gore Viafort Vascular Stent IVC Study, which is evaluating the investigational Gore Viafort vascular stent for the treatment of symptomatic inferior vena cava (IVC) obstruction with or without combined iliofemoral obstruction.

InterVene’s Recana Thrombectomy System Cleared by FDA

November 6, 2025—InterVene, Inc. recently announced that it has received 510(k) clearance from the FDA for its Recana thrombectomy catheter system, which is designed specifically for venous in-stent restenosis and native vessel obstructions.

Study Evaluates Incidence of and Risk Factors for IVC Thrombosis in Patients With IVC Filters

March 2, 2022—In a retrospective study of patients with an indwelling inferior vena cava (IVC) filter, Xiao and colleagues found a 2% incidence of IVC thrombosis, which was more commonly seen in male patients, those with neurologic disease, and those who received a Denali IVC filter (BD Interventional).

Systematic Review Evaluates Incidence, Outcomes, and Management of Venous Stent Migration

January 26, 2022—In a systematic review of published data from the last 25 years on recorded events of stent migration, Sayed et al found that migration events may be underreported due to a significant risk of publication bias.